Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 2/5 criteria met. Data as of 03/10/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 45.17%
Price change 2019 → 2020: 43.37%
Price change 2020 → 2021: 43.25%
Price change 2021 → 2022: -17.47%
Price change 2022 → 2023: -3.61%
Price change 2023 → 2024: -1.99%
Price change 2024 → 2025: 11.38%
Price change 2025 → 2026: 12.61%
Price change 2026 (year to date): 10.13%
Financial growth
Revenue CAGR (8 years): 9.01%
Earnings CAGR (8 years): 12.59%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.74
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 28.27
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 3.99% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="TMO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | 30.0 | 0.74 | +9.9 % | 🔒 |
| Amgen Inc. | 20.6 | 6.31 | +6.1 % | – |
| AstraZeneca PLC | 20.1 | 0.61 | +3.9 % | – |
| Roche Holding AG | 25.8 | 0.98 | +1.7 % | – |
| UnitedHealth Group Incorporated | 21.1 | 0.83 | +10.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Thermo Fisher Scientific Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 32.2 bn | 6.4 bn | 19.8 % | n/a |
| 2021 | 39.2 bn | 7.7 bn | 19.7 % | +21.7 % |
| 2022 | 44.9 bn | 7.0 bn | 15.5 % | +14.5 % |
| 2023 | 42.9 bn | 6.0 bn | 14.0 % | -4.6 % |
| 2024 | 42.9 bn | 6.3 bn | 14.8 % | +0.1 % |
| 2025 | 44.6 bn | 6.7 bn | 15.1 % | +3.9 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Thermo Fisher Scientific Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 4.5 bn | 8.5 bn | 8.1 bn | 5.6 bn | 10.1 bn |
| Total Debt | 36.3 bn | 36.1 bn | 36.4 bn | 32.8 bn | 39.4 bn |
| Net Debt | 31.9 bn | 27.5 bn | 28.3 bn | 28.8 bn | 29.5 bn |
| Equity | 40.8 bn | 44.0 bn | 46.7 bn | 49.6 bn | 53.4 bn |
| Total assets | 95.1 bn | 97.2 bn | 98.7 bn | 97.3 bn | 110 bn |
| Operating cash flow | 9.5 bn | 9.2 bn | 8.4 bn | 8.7 bn | 7.8 bn |
| Investments (capex) | 2.5 bn | 2.2 bn | 1.5 bn | 1.4 bn | 1.5 bn |
| Free cash-flow | 7.0 bn | 6.9 bn | 6.9 bn | 7.3 bn | 6.3 bn |
| Share buybacks | 2.0 bn | 3.0 bn | 3.0 bn | 4.0 bn | 3.0 bn |
| Dividends paid | 395 m | 455 m | 523 m | 583 m | 636 m |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Valuation and competitors
Thermo Fisher Scientific Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Thermo Fisher Scientific Inc. | 257 bn | 30.0 | 15.1 % |
| Danaher Corporation DHR | 162 bn | 28.9 | 14.7 % |
| Agilent Technologies, Inc. A | 49.3 bn | 30.1 | 18.8 % |
| Revvity, Inc. RVTY | 17.3 bn | 29.0 | 8.5 % |
| Bio-Rad Laboratories, Inc. BIO | 10.3 bn | 41.1 | 29.4 % |
| Waters Corporation WAT | 44.9 bn | 33.5 | 20.3 % |
| Bio-Techne Corporation TECH | 11.4 bn | 37.5 | 6.0 % |
| Qiagen N.V. QGEN | 10.4 bn | 20.8 | 20.3 % |
| Mettler-Toledo International Inc. MTD | 34.5 bn | 39.6 | 21.6 % |
| Sector median (NYSE) | 27.7 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Thermo Fisher Scientific Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Analysts' average target 707.29 USD, DCF value 446.24 USD, share price 694.76 USD.
Average target over the last 3 months: 758.93 USD (15 targets).
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 48.0 bn | 9.5 bn | 25.28 (25.17 / 25.42) | 27.5 | 15 |
| 2027 | 50.6 bn | 10.2 bn | 27.73 (26.93 / 29.21) | 25.1 | 16 |
| 2028 | 53.8 bn | 11.2 bn | 30.61 (27.37 / 32.35) | 22.7 | 6 |
Amounts in USD, the reporting currency.
Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.
Rating changes (12 months)
| Date | Firm | Before | After |
|---|---|---|---|
| 30/10/2026 | Argus Research | Buy | Buy |
| 23/10/2026 | Citigroup | Buy | Buy |
| 22/10/2026 | Baird | Outperform | Outperform |
| 22/10/2026 | RBC Capital | Sector Perform | Sector Perform |
| 22/10/2026 | Barclays | Overweight | Overweight |
Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Thermo Fisher Scientific Inc.: dividend history, last distributions, stock splits and earnings releases.
● Next ex-dividend date: 15/12/2026, 0.470 USD per share.
Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 15/12/2026 | 0.470 USD | 15/01/2027 |
| 15/09/2026 | 0.470 USD | 15/10/2026 |
| 15/06/2026 | 0.470 USD | 15/07/2026 |
| 13/03/2026 | 0.470 USD | 15/04/2026 |
| 15/12/2025 | 0.430 USD | 15/01/2026 |
| 15/09/2025 | 0.430 USD | 15/10/2025 |
| 13/06/2025 | 0.430 USD | 15/07/2025 |
| 14/03/2025 | 0.430 USD | 15/04/2025 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 21/10/2026 | 6.68 | 6.40 | +4.4 % |
| 23/07/2026 | 6.03 | 5.72 | +5.4 % |
| 23/04/2026 | 5.44 | 5.25 | +3.6 % |
| 29/01/2026 | 6.57 | 6.45 | +1.9 % |
| 22/10/2025 | 5.79 | 5.50 | +5.3 % |
| 23/07/2025 | 5.36 | 5.23 | +2.5 % |
Stock splits
| Date | Operation |
|---|---|
| 06/06/1996 | split: 3 shares for 2 |
| 25/05/1995 | split: 3 shares for 2 |
| 29/10/1993 | split: 3 shares for 2 |
| 03/11/1986 | split: 3 shares for 2 |
| 17/09/1985 | split: 3 shares for 2 |
| 04/01/1984 | split: 3 shares for 2 |
Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Thermo Fisher Scientific Inc.
Indices: S&P 500 (since 03/08/2004).
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| Vanguard Group | 34.1 m | 19.8 bn | 0.3 % | +0.9 % | 2025Q4 |
| State Street | 33.7 m | 16.9 bn | 0.2 % | +101.1 % | 2026Q2 |
| BlackRock | 30.9 m | 15.5 bn | 0.2 % | +1.6 % | 2026Q2 |
| Fidelity | 14.1 m | 7.1 bn | 0.3 % | +30.7 % | 2026Q2 |
| Morgan Stanley | 10.8 m | 5.4 bn | 0.3 % | -0.9 % | 2026Q2 |
| JPMorgan Chase | 8.5 m | 4.3 bn | 0.2 % | +25.1 % | 2026Q2 |
| Geode Capital Management | 8.4 m | 4.2 bn | 0.2 % | -0.3 % | 2026Q2 |
| Capital World Investors | 6.2 m | 3.1 bn | 0.4 % | -6.8 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 28/10/2026 | Britt Lisa P. | sale | 2.0 m USD |
| 31/08/2026 | Pettiti Gianluca | sale | 245,752 USD |
| 31/08/2026 | Pettiti Gianluca | sale | 2.3 m USD |
| 24/08/2026 | Casper Marc N | sale | 63,166 USD |
| 24/08/2026 | Casper Marc N | sale | 20,677 USD |
| 24/08/2026 | Casper Marc N | sale | 49,613 USD |
Elected officials' disclosures
| Date | Official | Side | Amount |
|---|---|---|---|
| 13/10/2026 | Ro Khanna | sale | $15,001 - $50,000 |
| 07/08/2026 | Ro Khanna | purchase | $1,001 - $15,000 |
| 12/12/2024 | Michael Rulli | sale | $1,001 - $15,000 |
| 27/03/2026 | Alan Armstrong | purchase | $1,001 - $15,000 |
| 10/07/2026 | Daniel Milton Newhouse | sale | $1,001 - $15,000 |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Thermo Fisher Scientific Inc.
What is the Thermo Fisher Scientific Inc. share price?
Latest recorded price: 700.22 USD on 13/11/2026, for a market cap of 259 bn USD.
What is the revenue of Thermo Fisher Scientific Inc.?
44.6 bn USD for fiscal year 2025, with net income of 6.7 bn USD (net margin 15.1 %).
Does Thermo Fisher Scientific Inc. pay a dividend?
Yes. Latest dividend: 0.470 USD per share, ex-dividend on 15/12/2026. Over 12 months: 1.84 USD. Yield on the latest known price: 0.3 %.
When does Thermo Fisher Scientific Inc. report its next earnings?
The next release is expected on 04/02/2027. EPS expected by analysts: 7.13.
What do analysts say about Thermo Fisher Scientific Inc.?
Out of 43 analysts: 36 buy or strong buy, 7 hold, 0 sell or strong sell. Average price target: 707.29 USD, i.e. +1.8 % from the share price.
What is the P/E ratio of Thermo Fisher Scientific Inc.?
Trailing 12-month P/E of 30.2, against 27.7 for the sector median on the same exchange (10-year median: 22.3).
Is Thermo Fisher Scientific Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US8835561023).
How many employees does Thermo Fisher Scientific Inc. have?
125,000 full-time employees according to the latest published profile.
Who runs Thermo Fisher Scientific Inc.?
Marc N. Casper is the company's chief executive.
Which large funds own Thermo Fisher Scientific Inc.?
As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, Fidelity, Morgan Stanley.